Lung cancer represents the leading cause of cancer‐related deaths worldwide.1 A subgroup of non‐small lung cancer (NSCLC) patients have been reported to have activating EGFR mutations,2 and responded well to first‐generation EGFR tyrosine kinase inhibitors (EGFR‐TKIs). This evidence concerns the gene EGFR and non-small cell lung carcinoma.